- Home
- HOWL vs APLT Comparison
HOWL vs APLT Comparison
Compare HOWL & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- APLT
- Stock Information
- Founded
- HOWL 2017
- APLT 2016
- Country
- HOWL United States
- APLT United States
- Employees
- HOWL N/A
- APLT N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- APLT Health Care
- Exchange
- HOWL Nasdaq
- APLT Nasdaq
- Market Cap
- HOWL 64.5M
- APLT 63.6M
- IPO Year
- HOWL 2021
- APLT 2019
- Fundamental
- Price
- HOWL $1.40
- APLT $0.41
- Analyst Decision
- HOWL Strong Buy
- APLT Buy
- Analyst Count
- HOWL 5
- APLT 6
- Target Price
- HOWL $7.20
- APLT $6.10
- AVG Volume (30 Days)
- HOWL 151.8K
- APLT 771.9K
- Earning Date
- HOWL 11-06-2025
- APLT 11-06-2025
- Dividend Yield
- HOWL N/A
- APLT N/A
- EPS Growth
- HOWL N/A
- APLT N/A
- EPS
- HOWL N/A
- APLT N/A
- Revenue
- HOWL N/A
- APLT $121,000.00
- Revenue This Year
- HOWL N/A
- APLT N/A
- Revenue Next Year
- HOWL N/A
- APLT $5,931.24
- P/E Ratio
- HOWL N/A
- APLT N/A
- Revenue Growth
- HOWL N/A
- APLT N/A
- 52 Week Low
- HOWL $0.60
- APLT $0.30
- 52 Week High
- HOWL $4.18
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- HOWL 56.16
- APLT 38.50
- Support Level
- HOWL $1.38
- APLT $0.40
- Resistance Level
- HOWL $1.49
- APLT $0.46
- Average True Range (ATR)
- HOWL 0.07
- APLT 0.03
- MACD
- HOWL 0.00
- APLT -0.01
- Stochastic Oscillator
- HOWL 55.00
- APLT 7.74
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.